HC Wainwright Has Positive Forecast for ASND FY2026 Earnings

Key Points

• HC Wainwright raised Ascendis Pharma’s FY2026 EPS forecast to $17.04 from $3.93, far above the $3.90 consensus estimate, while maintaining a Buy rating and $345 price target.
• Wall Street sentiment remains favorable, with the stock carrying an average Buy rating and a consensus price target of $310.05; other analysts have generally maintained Buy or Overweight ratings.
• Ascendis recently reported quarterly EPS of $1.03, missing the $1.71 consensus, although revenue of $387.22 million exceeded expectations. Shares opened at $260.25 and were down 1.1% in the latest session.

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a note issued to investors on Monday, August 31st. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $17.04 per share for the year, up from their previous forecast of $3.93. HC Wainwright currently has a "Buy" rating and a $345.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is $3.90 per share.

Several other equities research analysts have also recently commented on the stock. TD Cowen lifted their price target on shares of Ascendis Pharma A/S from $325.00 to $341.00 and gave the stock a "buy" rating in a research report on Friday, August 14th. Weiss Ratings raised shares of Ascendis Pharma A/S from a "sell (d)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an "overweight" rating for the company in a report on Friday, May 8th. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Finally, Jefferies Financial Group cut their price target on Ascendis Pharma A/S from $333.00 to $330.00 and set a "buy" rating on the stock in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Ascendis Pharma A/S has an average rating of "Buy" and a consensus price target of $310.05.

Ascendis Pharma A/S Trading Down 1.1%

Shares of ASND opened at $260.25 on Wednesday. The stock's fifty day simple moving average is $256.87 and its 200-day simple moving average is $239.75. The firm has a market capitalization of $16.23 billion, a PE ratio of 20.19 and a beta of 0.35. Ascendis Pharma A/S has a 12-month low of $186.05 and a 12-month high of $282.15. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The company had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently bought and sold shares of ASND. Cetera Investment Advisers bought a new position in shares of Ascendis Pharma A/S during the second quarter worth about $552,000. Rhumbline Advisers boosted its position in Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company's stock worth $249,000 after acquiring an additional 55 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Ascendis Pharma A/S by 66.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company's stock worth $645,000 after acquiring an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of Ascendis Pharma A/S by 83.4% in the second quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company's stock valued at $34,700,000 after purchasing an additional 91,412 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Ascendis Pharma A/S in the second quarter worth $897,000.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 2,000 shares of the firm's stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares in the company, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 40.00% of the company's stock.

Key Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis Pharma and BioMarin entered a binding term sheet for a global settlement and license agreement related to YUVIWEL (navepegritide). The agreement appears to reduce legal and commercial uncertainty surrounding the program and initially drove a strong move in the shares. Ascendis Pharma and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL
• Positive Sentiment: HC Wainwright dramatically raised its FY2026 EPS forecast to $17.04 from $3.93 while maintaining a Buy rating and a $345 price target. The new estimate is well above the broader full-year consensus of $3.90, signaling substantial expected earnings growth.
• Positive Sentiment: Wedbush reaffirmed its Outperform rating and $327 price target, implying substantial upside from the reference price of $260.25. Wedbush Reaffirms Ascendis Pharma Rating
• Neutral Sentiment: Ascendis Pharma received an average analyst rating of Buy, indicating that Wall Street sentiment remains favorable despite recent estimate changes. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for Q3 and Q4 2026 and every quarter listed for 2027. Its FY2027 estimate fell to $11.25 from $11.88, suggesting a slower near-term earnings ramp even though the firm retained its Buy rating and $345 target.
• Negative Sentiment: Bank of America reduced its price target to $304 from $306 while maintaining a Buy rating. The small cut is not a change in overall recommendation, but it may reinforce concerns about valuation or near-term execution. Bank of America Lowers Ascendis Pharma Price Target

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source